Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1865-8652

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection ; volume:37 ; number:5 ; day:11 ; month:4 ; year:2020 ; pages:2267-2274 ; date:5.2020
Advances in therapy ; 37, Heft 5 (11.4.2020), 2267-2274, 5.2020

Creator: Flamm, Steven L.
Kort, Jens
Marx, Steven E.
Strezewski, John
Dylla, Douglas E.
Bacon, Bruce
Curry, Michael P.
Tsai, Naoky
Wick, Nicole

Contributor: SpringerLink (Online service)

DOI: 10.1007/s12325-020-01301-5

URN: urn:nbn:de:101:1-2020071214373134977717

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Flamm, Steven L.
Kort, Jens
Marx, Steven E.
Strezewski, John
Dylla, Douglas E.
Bacon, Bruce
Curry, Michael P.
Tsai, Naoky
Wick, Nicole
SpringerLink (Online service)

Other Objects (12)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Response of treatment-naive brain metastases to stereotactic radiosurgery

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Response of treatment-naive brain metastases to stereotactic radiosurgery

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Response of treatment-naive brain metastases to stereotactic radiosurgery

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Response of treatment-naive brain metastases to stereotactic radiosurgery

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Response of treatment-naive brain metastases to stereotactic radiosurgery

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Response of treatment-naive brain metastases to stereotactic radiosurgery

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Related objects

Reset password